Total Payments
$3,013
2024 Payments
$112.97
Companies
20
Transactions
95
Medicare Patients
9,009
Medicare Billing
$728,040
Payment Breakdown by Category
Food & Beverage$2,978 (98.8%)
Education$34.95 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,978 | 94 | 98.8% |
| Education | $34.95 | 1 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $498.77 | 25 | $0 (2019) |
| ABBVIE INC. | $435.14 | 8 | $0 (2024) |
| Amgen Inc. | $417.34 | 7 | $0 (2023) |
| Celgene Corporation | $276.46 | 5 | $0 (2017) |
| Incyte Corporation | $230.05 | 10 | $0 (2024) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $169.05 | 3 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $142.47 | 3 | $0 (2019) |
| LEO Pharma Inc. | $131.14 | 8 | $0 (2022) |
| Almirall LLC | $113.90 | 1 | $0 (2023) |
| Allergan Inc. | $93.80 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $112.97 | 5 | ABBVIE INC. ($66.28) |
| 2023 | $578.11 | 15 | Incyte Corporation ($201.87) |
| 2022 | $282.60 | 6 | ABBVIE INC. ($112.90) |
| 2020 | $180.48 | 5 | Amgen Inc. ($87.15) |
| 2019 | $574.38 | 23 | PFIZER INC. ($326.73) |
| 2018 | $600.27 | 16 | Regeneron Healthcare Solutions, Inc. ($130.01) |
| 2017 | $683.94 | 25 | Celgene Corporation ($276.46) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $14.98 | General |
| Category: Dermatology | ||||||
| 09/06/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $31.28 | General |
| Category: IMMUNOLOGY | ||||||
| 06/27/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: IMMUNOLOGY | ||||||
| 05/01/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: DERMATOLOGY | ||||||
| 03/07/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: DERMATOLOGY | ||||||
| 12/20/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/26/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $112.06 | General |
| Category: IMMUNOLOGY | ||||||
| 10/10/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $11.40 | General |
| Category: Dermatology | ||||||
| 09/12/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $7.69 | General |
| Category: Dermatology | ||||||
| 06/26/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: Immunology | ||||||
| 05/25/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $11.61 | General |
| Category: Dermatology | ||||||
| 05/24/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.66 | General |
| Category: IMMUNOLOGY | ||||||
| 05/09/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $14.06 | General |
| Category: Dermatology | ||||||
| 05/02/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $14.00 | General |
| Category: Dermatology | ||||||
| 04/20/2023 | Almirall LLC | Klisyri (Drug) | Food and Beverage | In-kind items and services | $113.90 | General |
| Category: Dermatology | ||||||
| 04/20/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $11.53 | General |
| Category: Dermatology | ||||||
| 04/04/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $7.43 | General |
| Category: Dermatology | ||||||
| 03/29/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $124.15 | General |
| Category: Dermatology | ||||||
| 03/14/2023 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $116.85 | General |
| Category: Inflammation | ||||||
| 01/26/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $2.58 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Immunology | ||||||
| 12/12/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Immunology | ||||||
| 12/07/2022 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: DERMATOLOGY | ||||||
| 12/07/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $13.20 | General |
| Category: Dermatology | ||||||
| 11/02/2022 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $92.13 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 2,486 | 4,655 | $743,213 | $204,055 |
| 2022 | 14 | 1,930 | 3,566 | $512,175 | $144,888 |
| 2021 | 14 | 2,380 | 4,429 | $585,245 | $200,928 |
| 2020 | 15 | 2,213 | 4,108 | $472,375 | $178,169 |
Total Patients
9,009
Total Services
16,758
Medicare Billing
$728,040
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 536 | 699 | $167,760 | $45,925 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 324 | 412 | $140,080 | $37,091 | 26.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 359 | 446 | $102,580 | $36,287 | 35.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 254 | 331 | $91,025 | $20,425 | 22.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 372 | 511 | $68,985 | $18,061 | 26.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 60 | 86 | $41,710 | $9,984 | 23.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 286 | 1,807 | $36,140 | $9,614 | 26.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 113 | 130 | $16,250 | $5,735 | 35.3% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 36 | 48 | $21,949 | $4,811 | 21.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 66 | 100 | $14,000 | $4,047 | 28.9% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 12 | 12 | $14,568 | $3,675 | 25.2% |
| 17281 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 15 | 15 | $4,800 | $2,193 | 45.7% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 15 | 17 | $5,440 | $2,068 | 38.0% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 15 | 18 | $9,036 | $1,819 | 20.1% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 12 | 12 | $5,700 | $1,337 | 23.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $3,190 | $981.81 | 30.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 509 | 665 | $159,600 | $43,830 | 27.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 290 | 341 | $78,430 | $27,367 | 34.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 327 | 416 | $56,160 | $15,176 | 27.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 204 | 241 | $66,275 | $14,801 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 109 | 132 | $44,880 | $12,238 | 27.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 60 | 90 | $43,650 | $11,559 | 26.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 250 | 1,452 | $29,040 | $7,939 | 27.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 77 | 93 | $11,625 | $4,108 | 35.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 42 | 59 | $8,260 | $2,572 | 31.1% |
About Dr. Lynn Iler, MD
Dr. Lynn Iler, MD is a Dermatology healthcare provider based in East Greenwich, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356351126.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lynn Iler, MD has received a total of $3,013 in payments from pharmaceutical and medical device companies, with $112.97 received in 2024. These payments were reported across 95 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($2,978).
As a Medicare-enrolled provider, Iler has provided services to 9,009 Medicare beneficiaries, totaling 16,758 services with total Medicare billing of $728,040. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location East Greenwich, RI
- Active Since 08/08/2006
- Last Updated 05/11/2015
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1356351126
Products in Payments
- EUCRISA (Drug) $498.77
- Otezla (Drug) $454.09
- OPZELURA (Drug) $230.05
- SKYRIZI (Biological) $180.92
- Enbrel (Biological) $134.13
- DUPIXENT DUPILUMAB INJECTION (Biological) $130.01
- RINVOQ (Biological) $129.56
- Klisyri (Drug) $113.90
- TREMFYA (Drug) $106.32
- ENSTILAR (Drug) $105.55
- BOTOX COSMETIC (Biological) $93.80
- TECFIDERA (Drug) $79.36
- DUPIXENT (Drug) $78.08
- DUOBRII (Drug) $74.97
- REMICADE (Biological) $38.78
- Finacea (Drug) $33.67
- VTAMA (Drug) $31.71
- Erivedge (Biological) $26.82
- ADBRY (Biological) $25.59
- DORYX (Drug) $16.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in East Greenwich
Dr. John Kelly, Md/Phd, MD/PHD
Dermatology — Payments: $196,722
Dermatology $196,722
Dr. Anita Pedvis-Leftick, M.d, M.D
Dermatology — Payments: $29,371
Dermatology $29,371
Dr. Vincent Criscione
Dermatology — Payments: $10,736
Dermatology $10,736
Robert Dyer, M.d, M.D
Dermatology — Payments: $4,263
Dermatology $4,263
Alexandra Leonard, Md, MD
Dermatology — Payments: $3,469
Dermatology $3,469
Dr. Kathleen Carney-Godley, M.d, M.D
Dermatology — Payments: $1,793
Dermatology $1,793